European Prevention of Alzheimer's Dementia

European Prevention of Alzheimer's Dementia
Name	European Prevention of Alzheimer's Dementia
Abbreviation	EPAD
Formation	2014
Type	Research consortium
Headquarters	Edinburgh
Region served	Europe

European Prevention of Alzheimer's Dementia The European Prevention of Alzheimer's Dementia initiative coordinates preventative research across Edinburgh, London, Paris, Berlin, Madrid and other major European centers to accelerate interventions for cognitive decline. It links clinical networks in Scotland, England, France, Germany, Spain and partner institutions including University of Edinburgh, University College London, INSERM, Charité – Universitätsmedizin Berlin and Universitat de Barcelona to create large cohort resources. The project aligns with pan-European efforts such as Horizon 2020, Innovative Medicines Initiative and collaborations with agencies like the European Commission and agencies in Sweden, Italy.

Overview

EPAD established a platform trial model influenced by adaptive designs used in trials at University College London, Harvard Medical School, Massachusetts General Hospital, Johns Hopkins University and industry partners like Pfizer, Roche, GlaxoSmithKline, and Novartis. The program assembled longitudinal cohorts, biomarker repositories, and trial-ready populations drawn from sites including Karolinska Institutet, Aarhus University, KU Leuven, Trinity College Dublin and University of Oxford. Its governance involved advisory input from bodies such as World Health Organization, Alzheimer's Association, European Medicines Agency and national regulators in Belgium, Netherlands and Denmark.

History and Development

EPAD grew from meetings in London and project planning under Horizon 2020 with leadership linked to investigators at University of Edinburgh, University College London, Imperial College London, INSERM and Karolinska Institutet. Early planning referenced landmark studies at Framingham Heart Study, Rotterdam Study, Baltimore Longitudinal Study of Aging and datasets from Alzheimer's Disease Neuroimaging Initiative and registries maintained by National Health Service trusts in England and academic centers in France and Germany. The consortium model emulated networks such as European Research Council funded projects and public–private partnerships exemplified by IMI consortia.

Objectives and Research Strategy

Primary objectives included building a trial-ready cohort to test preventive interventions in preclinical stages identified by biomarkers used in studies at Mayo Clinic, Mount Sinai Hospital, Cambridge University Hospitals and imaging centers at University of California, San Francisco. EPAD emphasized adaptive trial designs inspired by trials at Yale University, Oxford University, Stanford University, and regulatory guidance from European Medicines Agency. The strategy incorporated cerebrospinal fluid biomarkers validated at University of Gothenburg, positron emission tomography methods from University of California, San Diego, and cognitive testing batteries developed at University College London and King's College London.

Key Trials and Findings

Key trials leveraged the EPAD Longitudinal Cohort to test multiple candidate therapeutics similar to approaches by Biogen, Eisai, AstraZeneca, Eli Lilly and Company and academic translational groups at University of Cambridge and University of Zurich. Findings reported improvements in cohort characterization, feasibility of adaptive seamless Phase II/III designs modelled on trials at Yale School of Medicine and biomarker stratification paralleling results from ADNI and studies at Mayo Clinic. Publications from EPAD investigators referenced statistical frameworks used at University of Warwick and outcome measures aligned with consensus from National Institute on Aging and networks like European Prevention Network.

Organization and Partnerships

The consortium structure included academic partners such as University of Edinburgh, University College London, INSERM, Charité – Universitätsmedizin Berlin, KU Leuven and Karolinska Institutet and industry collaborators including Pfizer, Roche, GlaxoSmithKline and Novartis. Strategic partners and funders included European Commission, Innovative Medicines Initiative, national research councils such as UK Research and Innovation, Agence Nationale de la Recherche, Deutsche Forschungsgemeinschaft and charitable organizations like Alzheimer's Society (England and Wales), Alzheimer Scotland, Fondation pour la Recherche sur Alzheimer and European Brain Council.

Funding and Ethics

Funding combined grants under Horizon 2020, contributions from pharmaceutical partners including AstraZeneca and philanthropic support from organizations like Wellcome Trust and national agencies such as Medical Research Council (United Kingdom). Ethical oversight referenced frameworks from European Medicines Agency, guidance from World Health Organization, and national ethics committees in Scotland, France, Germany and Spain to address consent, data sharing and use of genetic and biomarker data linked to resources from Biobank Japan and UK Biobank models.

Impact and Future Directions

EPAD influenced trial methodology in Europe and informed programs at institutions such as University of Oxford, Imperial College London, Karolinska Institutet, KU Leuven and industry pipelines at Biogen and Eli Lilly and Company. Future directions point toward integration with multinational initiatives like Horizon Europe, alignment with regulatory guidance from European Medicines Agency, expanded cohorts from Poland, Portugal and Greece, and continued public–private collaboration exemplified by Innovative Medicines Initiative models to accelerate preventive therapeutics.

Category:Alzheimer's disease research